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Highlights 
 Elevated corticomotoneuronal excitability is present in abstinent male amphetamine users. 
 Abstinent amphetamine users overestimate the grip force required to manipulate novel 
objects. 
 Elevated excitability and grip force overestimation is present months to years after ending 
drug use. 
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Abstract 
 
Objective 
The study aim was to determine if use of illicit amphetamines or ecstasy is associated with 
abnormal excitability of the corticomotoneuronal pathway and manipulation of novel objects with 
the hand.  
                                      
Methods 
Three groups of adults aged 18–50 years were investigated: individuals with a history of illicit 
amphetamine use, individuals with a history of ecstasy use but minimal use of other stimulants, and 
non-drug users. Transcranial magnetic stimulation was delivered to the motor cortex and the 
electromyographic response (motor evoked potential; MEP) was recorded from a contralateral hand 
muscle. Participants also gripped and lifted a novel experimental object consisting of two strain 
gauges and an accelerometer. 
                                                                                                
Results 
Resting MEP amplitude was larger in the amphetamine group (6M, 6F) than the non-drug and 
ecstasy groups (p<0.005) in males but not females. Overestimation of grip force during 
manipulation of a novel object was observed in the amphetamine group (p=0.020) but not the 
ecstasy group. 
                                                                                 
Conclusions 
History of illicit amphetamine use, in particular methamphetamine, is associated with abnormal 
motor cortical and/or corticomotoneuronal excitability in males and abnormal manipulation of 
novel objects in both males and females.  
 
Significance 
Abnormal excitability and hand function is evident months to years after cessation of illicit 
amphetamine use. 
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1. Introduction 
Use of illicit stimulant drugs is associated with long-lasting changes in movement and movement-
related brain regions. Adults with a history of illicit stimulant use exhibit an abnormally high level 
of excitability of the motor cortex and descending motor projection to the hand (Flavel et al., 
2012b), and altered hand function (King et al., 2010, Pearson-Dennett et al., 2014). Examples of the 
latter include overestimation of the grip force required to manipulate novel objects (Pearson-
Dennett et al., 2014) and taking longer to complete the grooved pegboard test than non-drug using 
controls (King et al., 2010, c.f. Pearson-Dennett et al., 2014). However, the class of stimulant drug 
associated with these changes is not yet known. Participants in the studies by Flavel et al. (2012) 
and Pearson-Dennett et al. (2014) had a history of primarily methamphetamine (average occasions 
of use >192) and ecstasy (average occasions of use >60) use, with lesser use of cocaine (average of 
6–8 occasions of use). Thus, it is conceivable that the abnormal excitability and hand function is 
associated with use of amphetamines (including methamphetamine) or ecstasy, rather than use of 
cocaine.  
 
Separating the long-lasting effects of amphetamines (including methamphetamine) from those of 
ecstasy is challenging in humans because a high percentage of amphetamine users have a history of 
ecstasy and other drug use (e.g. Darke et al., 2012, Todd et al., 2016b). An experimental approach 
that enables separation of the long-lasting effects of amphetamines from those of ecstasy involves 
comparison of individuals with a history of ecstasy use but minimal use of amphetamines, with 
individuals who have a history of amphetamine and ecstasy use. Use of this experimental approach 
has led to the discovery of abnormal substantia nigra morphology and symptoms of parkinsonism in 
abstinent amphetamine users (but not ecstasy users) and abnormal tremor in ecstasy users (Flavel et 
al., 2012a, Todd et al., 2016b). However, this experimental approach is challenging for participant 
recruitment because few regular ecstasy users have no or minimal use of amphetamines and/or 
cocaine (Palamar et al., 2017). 
 
The primary aim of the current study was to use the above experimental approach to determine i) if 
history of use of amphetamines or ecstasy is associated with abnormal hand function and 
excitability of the motor cortex and descending projection to hand muscles, and ii) if the abnormal 
excitability and hand function in this population are related to one another. Amphetamines and 
ecstasy (3,4-methylenedioxymethamphetamine or ‘MDMA’) disrupt monoamine neurotransmission 
and are toxic to predominantly dopaminergic and serotonergic neurons, respectively (Green et al., 
2003, Yamamoto et al., 2005). We hypothesised that use of illicit amphetamines but not ecstasy 
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would be associated with i) increased excitability of the motor cortex and/or corticomotoneuronal 
projection and ii) abnormal manipulation of novel objects (i.e. abnormal manipulation of an object 
during the first trial but not in subsequent trials). Evidence that supports a role for amphetamines 
comes from the literature on patients with Parkinson’s disease, a disease characterised by 
degeneration of predominantly dopaminergic neurones (Fearnley et al., 1991). Both young-to-
middle aged abstinent stimulant users and patients with Parkinson’s disease exhibit increased 
resting motor cortical and/or corticomotoneuronal excitability (Cantello et al., 1991, Flavel et al., 
2012b) and overestimation of the grip force required to lift a novel object (Fellows et al., 2004, 
Pearson-Dennett et al., 2014). There is also overlap between the pathophysiology of Parkinson’s 
disease and methamphetamine-induced toxicity (e.g. oxidative stress, mitochondrial dysfunction, 
and excitotoxicity, Yamamoto et al., 2005, Ambrosi et al., 2014), and use of methamphetamine is a 
significant risk factor for developing Parkinson’s disease later in life (Callaghan et al., 2010, Todd 
et al., 2016b). Evidence that supports a role for abnormal manipulation of a novel object, but not 
subsequent handling of the same object, is preservation of motor learning in individuals with a 
history of illicit stimulant use (e.g. Pearson-Dennett et al., 2014, Todd et al., 2016a). 
  
A secondary aim was to investigate the effect of sex on excitability and hand control because 
amphetamine dependency and the effect of amphetamines on the brain can differ between males 
and females (for review see Dluzen et al., 2008). Female methamphetamine users report a greater 
severity of psychiatric and drug problems, and a more rapid transition from first use to problem use, 
than male methamphetamine users (Simpson et al., 2016). However, this does not translate to 
consistently greater abnormalities in brain structure and/or function in females. For example, 
widespread reductions in gray matter volume has been observed in abstinent female 
methamphetamine users but not in abstinent males (Regner et al., 2015) whereas male 
methamphetamine users exhibit more hypoperfused areas of the frontal and parietal lobes than 
female methamphetamine users (Chang et al., 2002), and greater severity of white-matter signal 
hyperintensities (Bae et al., 2006). We hypothesised that the magnitude of change in the excitability 
of the motor cortex and/or corticomotoneuronal projection to the hand, and application of grip force 
during manipulation of novel objects, would be greater (more abnormal) in male amphetamine users 
than female amphetamine users. This hypothesis is based on the observation that testosterone is 
toxic to dopaminergic neurons experiencing oxidative stress (Holmes et al., 2016), and oxidative 
stress is present in dopaminergic neurons that are exposed to amphetamine and/or 
methamphetamine (Yamamoto et al., 2005). The results of the current study will further 
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understanding of the long-lasting consequences of amphetamine and ecstasy use on the control of 
movement, and may broaden discussion on treatment and rehabilitation practices in this population.  
 
2. Methods 
Ninety-eight participants completed one or two studies to investigate hand function (Study 1) and 
excitability of the motor cortex and descending pathway to the hand (Study 2; 32 participants 
completed both studies). Each study involved three groups of adults aged 18–50 years. The target 
group consisted of adults with a history of illicit amphetamine and/or methamphetamine use (≥5 
occasions of use; ‘amphetamine’ group). The two control groups consisted of i) adults with a 
history of ecstasy use (≥5 occasions) but minimal use of amphetamine and/or methamphetamine 
(≤3 occasions; ‘ecstasy’ group) and ii) adults with a history of minimal cannabis use (≤2 occasions) 
and no other illicit drug use (‘non-drug’ group). We sought to match the three groups for sex and 
handedness, and to match history of post-drug use depression and/or anxiety in the amphetamine 
and ecstasy groups. Some of the data has been published in a different form (Flavel et al., 2012b, 
Pearson-Dennett et al., 2014). The study was approved by the University of South Australia Human 
Research Ethics Committee and conducted according to the World Medical Association Code of 
Ethics (Declaration of Helsinki). Written informed consent was obtained.  
  
2.1. Screening 
Each participant completed several screening tests including a urine drug screen (PSCupA-
6MBAU; US Diagnostics Inc.), transcranial magnetic stimulation (TMS) safety screen (Rossi et al., 
2009), neuropsychological assessment (Verbal Trails, Logical Memory I and II, Verbal Fluency, 
Digit Span forwards and backwards; Wechsler, 1981, Benton et al., 1983, Wechsler, 1987, Grigsby 
et al., 1995), and questionnaires to document recent symptoms of depression (Beck Depression 
Inventory-II; Beck et al., 1996), hand dominance (Edinburgh Handedness Inventory; Oldfield, 
1971), and lifetime history of licit (alcohol and tobacco) and illicit drug use (Flavel et al., 2012b, 
Pearson-Dennett et al., 2014). For each licit and illicit drug used, age of first use, duration and 
frequency of use, dose (if known), and time since last use were documented. The number of drug 
overdoses experienced and treatment for drug dependency were also noted. 
 
General exclusion criteria included i) contraindications for TMS, ii) prior diagnosis of a 
neurological trauma or disease/disorder that affects movement, iii) current use of a medication that 
alters motor cortical excitability, iv) frequent illicit opioid use (i.e. >5 times per year) and v) poor 
performance on three or more of the tested cognitive domains (for details see Pearson-Dennett et 
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al., 2014). Drug-using participants who had been diagnosed with depression and/or anxiety after 
first use of an illicit drug, and who were not currently being medicated for the condition, were 
allowed to participate due to the association between drug use and affective disorders (Dyer et al., 
2005, Taurah et al., 2014). Participants were also excluded if they returned a positive urine test for 
amphetamine, methamphetamine, MDMA, opioids, cocaine, and/or benzodiazepines. Participants 
who had a positive urine test for cannabis (tetrahydrocannabinol) were allowed to participate if self-
reported use of cannabis occurred >12 hours prior to testing. This exemption was required because 
the body can retain tetrahydrocannabinol for up to 80 days after last use (Grotenhermen, 2003). 
Participants with a non-neurological condition that may affect hand function (e.g. arthritis or prior 
finger injury) were excluded from participating in Study 1. 
 
2.2. Experimental Protocol 
In Study 1, participants (n=46 non-drug group, n=24 ecstasy group, n=19 amphetamine group) 
completed one experiment involving tests of hand function, using a previously published protocol 
(Pearson-Dennett et al., 2014). The experiment began with placement of two surface 
electromyographic (EMG) electrodes (Ag-AgC1, 10 mm diameter, inter-electrode distance: 3 cm) 
over the tendon and belly of the first dorsal interosseous (FDI) muscle on the dominant hand. EMG 
activity was amplified (300 or 1,000 times), sampled at 2,000 Hz, and filtered (20–1,000 Hz) using 
a data acquisition system (1902 with Power 1401 Interface and Signal software, Cambridge 
Electronic Design, Cambridge, UK). 
 
Participants sat on a chair in front of a table and performed three tasks with their dominant hand. 
The first task involved gripping and lifting an experimental apparatus (Fig. 1A) that consisted of 
two load cells (model MPL-100; Transducer Techniques, Temecula, CA, USA) and a dual axis 
accelerometer (±2 g, model ADXL311J, RS Components Pty Ltd, Smithfield, Australia). The load 
cells were mounted at 90º to one another for measurement of horizontal grip force and vertical load 
force and the total mass of the experimental apparatus was 342 g. Participants touched the apparatus 
on two polished brass disks mounted 35 mm apart, on opposing sides of the grip load cell. 
Participants were instructed to use their index finger and thumb (pinch grip) to ‘lift the object off 
the table to the height indicated (~10 cm), hold the object there for 3 s, and then place it back on the 
table’. The task duration was ~6 s and lifting the apparatus occurred predominantly through elbow 
flexion. The experimenter demonstrated the task before the participants’ first attempt and practice 
was not allowed. Participants performed two trials with 3–5 s rest between trials. 
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The second task involved three brief (2–3 s) maximal voluntary contractions (MVCs) to allow for 
normalization of certain parameters measured during the grip and lift task. MVCs were completed 
with a pinch grip and participants were not required to lift the apparatus off the table. Each MVC 
was separated by ~1 min of rest to minimize fatigue. The experimenter provided visual feedback of 
force and verbal encouragement during MVCs.  
 
In the final task, participants completed three trials of the grooved pegboard test. The task involved 
placing key-shaped pegs into corresponding holes (model 32025, Lafayette Instrument Company, 
Lafayette IN, USA), as fast as possible and in a set sequence. The time to complete each trial was 
recorded and a 1-min rest was provided between trials. 
 
In Study 2, participants (n=18 non-drug group, n=11 ecstasy group, n=12 amphetamine group) 
completed one experiment involving TMS, using a previously published protocol that successfully 
differentiated stimulant users from non-drug users and cannabis users (Flavel et al., 2012b). The 
age-range of participants in Study 2 was restricted to 18–33 years to minimise the effect of age on 
motor cortical excitability (Pitcher et al., 2003). Two surface electromyographic (EMG) electrodes 
(Ag-AgC1, 10 mm diameter, inter-electrode distance: 3 cm) were positioned on the dominant hand, 
over the first dorsal interosseous muscle belly and tendon. EMG activity was recorded with the 
same data acquisition system as that described in Study 1. Single-pulse TMS was delivered (~0.2 
Hz) to the first dorsal interosseous representation of the contralateral motor cortex using a Magstim 
200
2
 stimulator, BiStim
2 
UI controller, and a figure-of-eight coil (90-mm external diameter with 
handle pointing posteriorly at ~45˚ to the midline and tangentially to the skull; Magstim Co., 
Whitland, UK). Resting motor threshold was measured first and was defined as the minimum 
intensity that evoked a motor evoked potential (MEP) of >50 µV in amplitude in five out of ten 
consecutive stimuli (Rossini et al., 1994). A further fifteen stimuli were then delivered during 
relaxation, at an intensity of 130% resting motor threshold, to assess resting motor cortex and/or 
corticomotoneuronal excitability. Fifteen stimuli were then delivered, at the same intensity, during 
weak contraction of the target first dorsal interosseous muscle (via abduction of the index finger 
against a 53 g mass suspended from the distal interphalangeal joint). Stimuli delivered during weak 
contraction enabled measurement of the silent period (an index of GABAB-mediated intracortical 
inhibition) and movement-induced facilitation of motor cortex and corticomotoneuronal excitability 
(Ziemann, 2004). 
 
2.3. Data Analysis and Statistics 
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Group data are presented as mean±standard deviation, except for the output of regression analyses 
which are reported as mean±standard error. All data were assessed for normality with Shapiro-
Wilks test. One-way analysis of variance (ANOVA) was used for between-group comparison of 
participant characteristics, and alcohol and tobacco use. Data were analysed in Stata v.14 software 
(StataCorp, Texas, USA). Statistical significance was set at p<0.05. 
 
In Study 1, the grip and lift task was divided into a lift (0 s (lift onset)−1.5 s) and hold (1.5−2.5 s) 
phase (for example see Fig. 1B-D). Fifteen parameters were measured in the lift phase to provide 
information about grip strategy, kinematics and kinetics of the lifting action, and the coupling 
between grip and load force. In the lift phase, measurement of grip and lift onset involved applying 
a low-pass filter (20 Hz) to the raw force traces and then calculation of the rate of change in grip 
force (dGF⁄dt) and load force (dLF/dt). The onset was defined as the time of the initial increase in 
the derivative of force (above the noise level) that lead to attainment of the maximum derivative. 
The preload duration (grip onset relative to lift onset) and the maximum rate of change in force 
(dGF/dtmax and dLF/dtmax) were also calculated. The temporal relationship between the grip force 
and load force was measured by cross-correlating the rate of change in grip force (dGF⁄dt) and load 
force (dLF⁄dt) (Flanagan et al., 1997). dLF⁄dt was moved in 2.5 ms increments (sampling 
resolution) relative to dGF⁄dt until the maximal cross-correlation coefficient (ρ) was attained (IBM 
SPSS Statistics 20, Armonk NY, USA). The shift in time required to attain the maximum cross-
correlation coefficient reflects the difference in time between the change in load force and the 
change in grip force, and is indicative of grip strategy. A negative time shift (grip force leads load 
force) indicates a primarily anticipatory grip strategy and a positive time shift (grip force lags load 
force) indicates a primarily reactive grip strategy. Peak force, time-to-peak force, peak acceleration, 
time-to-peak acceleration, minimum load force (degree of downward force application before lifting 
the object), and the root mean square (RMS) EMG were also measured in the lift phase from raw 
traces. Three parameters were measured in the hold phase. These included RMS EMG, mean grip 
force, and the grip force coefficient of variation (%). For brief maximal voluntary contractions, 
RMS EMG and mean grip force were calculated over a 1 s period. 
 
Data from the grip and lift task and grooved pegboard test were analysed with mixed effects models 
in Stata v.14 software (StataCorp, Texas, USA). The models included fixed effects of ‘Group’, 
‘Trial’ and their interaction (‘Group’ x ‘Trial’). A random-effects intercept was included to account 
for between-participant variability. Maximal pinch grip strength was analysed with linear regression 
analysis. Raw data that violated model assumptions (i.e. distribution and homoscedasticity of the 
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residuals) were transformed and the models run on the transformed data. The effects of sex, age, 
and lifetime alcohol use were investigated on hand function parameters. Age and lifetime alcohol 
use were not predictors of any hand function parameters and therefore excluded from all models. 
Sex was found to be a significant predictor of maximal pinch grip strength and performance on the 
grooved pegboard test, and thus was included in the final analysis of these parameters. Planned 
contrasts were performed on trial one for peak grip force (raw) and maximal rate of change in grip 
force, and trial one of the grooved pegboard test. Contrasts were used to calculate the main effects 
of ‘Group’, ‘Trial’, ‘Group’ x ‘Trial’, and/or ‘Sex’ and are reported as either Chi square (grip and 
lift task, grooved pegboard task) or F-statistic (maximal pinch grip strength). Results of the models 
are reported (in the text and Supplementary Table S1) as transformed coefficient±standard error. All 
graphs show raw data to aid interpretation. Pearson Product Moment or Spearman Rank Order 
correlation were used to investigate the relationship between hand function and amphetamine drug-
use parameters (age of onset of use, number of occasions of use, duration of abstinence) in the 
amphetamine group (SigmaPlot 11.0; Sysat Software Inc). 
 
In Study 2, peak-to-peak MEP amplitude was measured in each trial. Resting MEPs with voluntary 
EMG activity prior to the stimulus were excluded from the analysis. During weak contractions, the 
duration of the silent period and the amount of voluntary EMG activity prior to the stimulus (RMS 
EMG amplitude over a 100 ms period) were also measured in each trial. MEP characteristics, silent 
period duration, and RMS EMG were analysed with a linear regression analysis in Stata v.14 
software (StataCorp, Texas, USA). The resting and active TMS conditions were analysed 
separately. MEP latency partly depends on the distance between the motor cortex and target muscle. 
Thus, height was included as a factor in the analysis of MEP latency. The effects of sex, age, and 
lifetime alcohol use were investigated on TMS parameters. Age and lifetime alcohol use were not 
predictors of any TMS parameters and thus were excluded from all models. Sex was found to be a 
significant predictor of MEP amplitude, and was therefore included in the final analysis of this 
parameter. Raw data that violated model assumptions (i.e. distribution and homoscedasticity of the 
residuals) were transformed and the models run on transformed data. Contrasts were used to 
calculate the main effects of ‘Group’, ‘Sex’, and ‘Group’ x ‘Sex’ and are reported as the F-statistic. 
All graphs show raw data to aid interpretation. Results of the models are reported (in the text and 
tables) as transformed mean±standard error. Pearson Product Moment or Spearman Rank Order 
correlation were used to investigate the relationship between TMS parameters and drug use 
characteristics in the amphetamine group. Pearson Product Moment or Spearman Rank Order 
correlation were also used to investigate the relationship between TMS and hand function 
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parameters in participants in the amphetamine group who completed both Study 1 and 2 (n=9; 
SigmaPlot 11.0; Sysat Software Inc). 
 
3. Results 
3.1. Participant characteristics 
Table 1 shows participant characteristics for each group in Study 1 and 2. The groups were matched 
for handedness (laterality quotient) and years of education, and performance on the 
neuropsychological tests did not significantly differ between the non-drug and drug-using groups. 
The groups were also matched for sex, except for the ecstasy group in Study 2 which had fewer 
females. The groups did, however, significantly differ in age (Study 1: F2,86=13.37, p<0.001, Study 
2: F2,38=5.27, p=0.010). The average age of the amphetamine group was 4–9 years older than the 
non-drug (Study 1: P<0.001, Study 2: p=0.038) and ecstasy (Study 1: p<0.001, Study 2: p=0.013) 
groups. The groups also differed significantly on the Beck Depression Inventory II (Study 1: 
F2,86=3.32, p=0.041, Study 2: F2,38=8.56, p<0.001). More symptoms of depression were reported in 
the ecstasy (Study 1: p=0.036, Study 2: p=0.005) and amphetamine (Study 2: p=0.003) groups than 
in the non-drug group. 
 
Lifetime use of alcohol (Study 1: F2,77=46.80, p<0.001, Study 2: F2,30=9.82, p<0.001) and tobacco 
(Study 1: F2,86=37.40, p<0.001, Study 2: F2,24=4.10, p=0.029) also differed significantly between 
the groups. Use of alcohol and tobacco was greatest in the amphetamine group and least in the non-
drug group (Table 1). Poly-drug use was common in the ecstasy and amphetamine groups, but 
lifetime use of ecstasy and hallucinogens did not differ between the drug-using groups. The 
amphetamine group reported significantly greater lifetime use of cannabis than the ecstasy group 
(p=0.002) in Study 1 but not Study 2. In the ecstasy group, the average duration of abstinence from 
cannabis was 0.4±0.7 years in Study 1 and 0.2±0.3 years in Study 2 and the average duration of 
abstinence from ecstasy was 0.5±0.8 years in Study 1 and 0.5±0.6 years in Study 2. In the 
amphetamine group, the average duration of abstinence from cannabis was 0.7±2.3 years in Study 1 
and 0.3±0.5 years in Study 2 and the average duration of abstinence from ecstasy was 3.9±4.4 years 
in Study 1 and 2.2±2.7 years in Study 2. The average duration of abstinence from amphetamines 
was 3.5±4.6 years in Study 1 and 1.8±2.2 years in Study 2. Urine data is missing for one control 
participant due to mislabelling (Study 1) and a small number of drug-using participants tested 
positive for THC, but none reported use of cannabis in the 12 hours prior to testing (Study 1: n=5 
ecstasy group, n=3 amphetamine group, Study 2: n=3 ecstasy group, n=2 amphetamine group). 
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3.2. Study 1: Hand function 
Figure 1B-D shows examples of raw data from the grip and lift task, for one participant in each 
group. Grip force and load force increased in parallel, and the initial increase in acceleration 
indicates the time at which the object began to accelerate. After peak grip force was attained, a 
slight decrease in grip force occurred and this was followed by a plateau while the object was held 
above the table in a stationary manner. During the plateau, grip force was 1.7−2.6 times higher than 
the load force, suggesting a modest safety margin to prevent the object from slipping. Three 
examples of the temporal relation between grip force and load force are displayed in Fig. 1E-G. 
Data in Fig. 1 suggest that the participant in the amphetamine group performed the task with a 
higher grip force than the participant in the non-drug and ecstasy group. 
 
Statistical analysis of group data for the grip and lift task and grooved pegboard task involved 
confirming learning across trials and then focusing on trial 1 (with planned contrasts) to investigate 
manipulation of novel objects (re an object is only novel during the first trial). Several grip and lift 
parameters improved across trials confirming preservation of motor learning in the drug-using 
groups. There was a significant main effect of trial on the raw (χ2(1)=57.43, p<0.001) and 
normalised (χ2(1)=58.14, p<0.001) peak grip force and maximum rate of change in grip force 
(χ2(1)=18.33, p<0.001) during the lift phase of the grip and lift task. The peak grip force (Fig. 2A) 
and maximum rate of change in grip force (Fig. 2C) decreased across trials. The mean grip force 
(raw force: χ2(1)=5.5, p=0.019, Fig 2B, normalised force: χ2(1)=5.61, p=0.018), mean load force 
(χ2(1)=6.28, p=0.012, Fig 2B), and the safety margin for error (mean grip force/load force; 
χ2(1)=5.19, p=0.023) during the hold phase also decreased significantly across trials, whereas the 
maximum cross-correlation coefficient increased significantly (i.e. better coupling between grip 
force and lift force, χ2(1)=39.76, p<0.001, Fig. 2D). Planned contrasts revealed a significant 
between-group difference in the raw peak grip force and maximum rate of change in grip force in 
trial one but not trial two. In trial one, raw peak grip force (Fig. 2A) and the maximum rate of 
change in grip force (dGF/dt; Fig. 2C) were significantly larger in the amphetamine group than in 
the non-drug (coefficient±standard error; peak grip force: 0.233±0.101, p=0.020; dGF/dt: 
0.295±0.132, p=0.025) and ecstasy (peak grip force: 0.227±0.113, p=0.045; dGF/dt: 0.274±0.148, 
p=0.065) groups. However, no between-group differences in raw peak grip force or the maximum 
rate of change in grip force were observed between the non-drug and ecstasy groups. No other 
significant effects of trial, group, or sex were observed for parameters measured during the grip and 
lift task. 
 
  
14 
 
 
 
In the grooved pegboard test, performance time decreased (i.e. performance improved) across trials 
(χ2(2)=338.99, p<0.001, Fig. 2E). Planned contrasts revealed a significant between-group difference 
in performance time between the amphetamine group and non-drug group in trial one 
(coefficient±standard error: 0.081±0.035, p=0.020) but not in trial two or three. Sex was also found 
to be a significant predictor of performance on the grooved pegboard test. On average, males took 5 
s longer to complete the pegboard task than females (60.9±9.4 s versus 55.5±3.8 s, p<0.001). No 
other between-group differences were observed for the grooved pegboard test. 
 
Maximal pinch grip strength significantly differed between the groups (F2,83=8.76, p<0.001) and 
between males and females (F1,83=45.40, p<0.001). The average force during the brief maximal 
voluntary contractions was larger in the amphetamine group (70.8±18.9 N) than in the non-drug 
group (55.5±15.3 N; p=0.002) but did not differ to that of the ecstasy group (62.5±14.3 N). The 
non-drug and ecstasy groups also did not differ in average force during the brief maximal voluntary 
contractions. As expected, males (68.1±15.9 N) had a greater pinch grip strength than females 
(48.1±9.2 N, p<0.001) but, there was no group-by-sex interaction on maximal pinch grip strength. 
 
There was no correlation between amphetamine drug-use parameters (age of first use, number of 
occasions of use, duration of abstinence) and hand function parameters in the amphetamine group. 
 
3.3 Study 2: Motor cortical excitability 
Figure 3A shows averaged resting EMG traces recorded in a typical participant from each group, 
and the size of the MEP following stimulation. The amplitude of the resting MEP was larger in the 
amphetamine participant than in the non-drug-using and ecstasy-using participants. Figure 3B 
shows group data for resting MEP amplitude. There was no main effect of group on resting MEP 
amplitude but there was a significant group-by-sex interaction (F2,35=5.63, p=0.008, Fig. 3B). In 
males, resting MEP amplitude was significantly larger in the amphetamine group than in the non-
drug (coefficient±standard error; 1.19±0.30, p=0.001) and ecstasy groups (1.02±0.34, p=0.005) but, 
there was no difference between the non-drug and ecstasy groups. In females, resting MEP 
amplitude was significantly smaller in the amphetamine group than in the non-drug using group (-
1.59±0.48, p=0.002), but there was no difference between the two female ecstasy participants and 
the non-drug or amphetamine groups. No significant main effect of group or group-by-sex 
interaction was observed for resting motor threshold (non-drug: 47±8%, ecstasy: 43±7%, 
amphetamine: 46±5% of stimulator output), or other MEP parameters measured during relaxation 
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or muscle contraction. In the amphetamine group, there was no correlation between TMS 
parameters and i) amphetamine drug-use parameters or ii) object manipulation parameters. 
 
4 Discussion 
History of illicit stimulant use is associated with abnormal manipulation of novel objects (Pearson-
Dennett et al., 2014) and elevated excitability of the motor cortex and descending pathway from the 
motor cortex to hand muscles (Flavel et al., 2012b). The results of the current study demonstrate 
that these abnormalities are associated with use of illicit amphetamines, primarily 
methamphetamine, and not use of ecstasy. 
 
When gripping and lifting a novel object (in trial 1), abstinent amphetamine users utilized a grip 
force that was 20% larger than non-drug users and ecstasy users. This suggests that individuals with 
a history of illicit amphetamine use overestimate the grip force that is required to lift a novel object 
and as a result, manipulate new objects in a manner that is less efficient. Estimation of the grip force 
required to lift a novel object begins prior to touching the object and is thought to engage an internal 
model that incorporates the objects’ physical properties (Westling et al., 1984), prior experience 
gripping and lifting similarly shaped objects (Augurelle et al., 2003), sensory feedback (Jenmalm et 
al., 1997), and the individual’s safety margin to prevent slip (for review see Johansson, 1998, 
Flanagan et al., 2006). The results of the current study suggest that this internal model may be 
altered in individuals with a history of illicit amphetamine use. Such alterations in movement 
planning may contribute to the poor initial performance of the grooved pegboard test in the 
amphetamine group relative to the non-drug group. Interestingly, the deficits in movement planning 
can be overcome with practice. Improved performance of the grip and lift task and grooved 
pegboard task occurred across trials in the amphetamine group, and performance in the subsequent 
trial/s did not differ between the groups. 
 
The motor cortices (primary motor cortex, supplementary motor area, and premotor cortex) provide 
descending input to spinal motoneurons that innervate muscles in the arm and hand (for review see 
Matelli et al., 2004). The amplitude of the MEP evoked by TMS provides an index of excitability in 
this pathway (Hess et al., 1987, Baker et al., 1995). Resting MEP amplitude differed between the 
groups in males and females. Resting MEP amplitude was significantly larger in male amphetamine 
users than in the male non-drug users and ecstasy users. This suggests that the net basal excitability 
of the motor cortices, corticospinal tract, and/or spinal motoneurones is abnormally high in males 
with a history of illicit amphetamine use. Increased excitability in this pathway could theoretically 
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arise from one, or a combination of, the following mechanisms: i) increased depolarization of 
excitatory interneurons in the motor cortex, ii) decreased depolarization of inhibitory interneurons 
in the motor cortex, iii) increased depolarization of pyramidal neurons that descend from the motor 
cortex to the spinal cord, and/or iv) changes in the excitability of spinal interneurons and 
motoneurons. Two lines of evidence suggest that reduced intracortical inhibition is unlikely. First, 
the duration of the silent period did not differ between groups in the current study, suggesting that 
GABAB-mediated intracortical inhibition within the motor cortex is unaltered (Ziemann, 2004). 
Second, GABAA-mediated intracortical inhibition, measured with paired-pulse TMS, is also 
unaltered in individuals with a history of mixed stimulant use (Flavel et al., 2012b). In females, 
resting MEP amplitude was significantly lower in amphetamine users than in non-drug users. 
However, the magnitude of reduction was small and there was no difference observed between the 
ecstasy group and the amphetamine or non-drug groups. 
 
There was no association between elevated basal excitability in the motor cortex and/or 
corticomotoneuronal pathway and overestimation of grip force during manipulation of novel objects 
in the amphetamine group. The relationship between abnormal excitability and motor planning may 
be better explored with application of TMS over the premotor or supplementary motor cortices 
immediately prior to gripping and lifting a novel object (e.g. Dafotakis et al., 2008, White et al., 
2013). There was also no association between the number of occasions of amphetamine use and 
hand function and TMS parameters. This suggests that dose, which is difficult to quantify 
retrospectively in humans, may be a more important factor than occasions of use. This view is 
supported by a significant dose-dependent relationship between amphetamine use and neurotoxicity 
in rodents, primates, and humans (Yamamoto et al., 2010). 
 
Identifying the mechanisms that underlie the elevated corticomotoneuronal excitability and altered 
manipulation of novel objects in the amphetamine group is challenging. The abnormal excitability 
and manipulation of novel objects is unlikely to reflect a generalised change in cortical function as 
the groups did not differ in neuropsychological performance. An acute effect of amphetamines is 
not possible because all participants returned a negative urine screen for amphetamines. Use of 
cannabis, ecstasy, alcohol, and tobacco is also unlikely to play a major role because resting MEP 
amplitude is unchanged in a small sample of alcohol-dependent patients with uncertain history of 
illicit drug use (Conte et al., 2008), and participants in the ecstasy group had a history of both 
ecstasy and cannabis use and resting excitability did not differ between the ecstasy and non-drug 
using groups. 
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The drug most likely to be associated with the elevated corticomotoneuronal excitability and altered 
manipulation of novel objects is methamphetamine. Methamphetamine was the main amphetamine 
drug consumed by participants in the amphetamine group. Methamphetamine is toxic to primarily 
dopaminergic neurones and induces long-lasting changes in dopaminergic neurotransmission 
(Yamamoto et al., 2010). There is rich dopaminergic innervation of the motor cortex in rodents 
(Awenowicz et al., 2002) and primates (Goldman-Rakic et al., 1989), and spontaneous discharge of 
pyramidal tract neurones decreases with local application of dopamine (Awenowicz et al., 2002). 
Thus, methamphetamine-induced changes in dopaminergic neurotransmission could alter basal 
excitability of the motor cortex and/or corticomotoneuronal pathway. The long-lasting effects of 
methamphetamine on dopaminergic neurotransmission could also partly explain why excitability 
and manipulation of novel objects is abnormal in individuals who had abstained from 
amphetamines for an average of 1.8 years. 
 
The elevated corticomotoneuronal excitability in male amphetamine users but not female 
amphetamine users could be related to levels of gonadal steroid hormones. Testosterone is toxic to 
dopaminergic neurons experiencing oxidative stress in cell culture (Holmes et al., 2016), and 
oxidative stress is present in dopaminergic neurons that have been exposed to amphetamine and/or 
methamphetamine (Yamamoto et al., 2005). Conversely, estrogen can protect nigrostriatal 
dopaminergic neurons against neurotoxicity induced by methamphetamine or MPTP (Dluzen et al., 
1996, Miller et al., 1996). Healthy adult females also have a higher density of dopamine 
transporters in the striatum than males (e.g. rodents: Rivest et al., 1995, e.g. humans: Lavalaye et 
al., 2000) and thus methamphetamine-induced loss of dopamine transporters (McCann et al., 1998, 
Volkow et al., 2001) could lead to greater alterations in neural circuitry and motor function in males 
compared to females. 
 
This study has three limitations. First, lifetime use of alcohol and tobacco was higher in the 
amphetamine group than in the ecstasy and non-drug groups. The number of participants in the 
amphetamine group who had a history of heavy drinking, according to the 2015-2020 Dietary 
Guidelines for Americans, was 37% compared to 21% for the ecstasy group (U.S. Department of 
Health and Human Services and U.S. Department of Agriculture, 2015). While the acute effects of 
alcohol on excitability have been investigated, along with the efficacy of repetitive TMS in treating 
alcohol and tobacco addiction (Barr et al., 2011, Loheswaran et al., 2016a, Loheswaran et al., 
2016b), the long-lasting effects of alcohol and/or tobacco use on resting MEP amplitude are 
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unknown. Second, it is not possible to determine in humans if methamphetamine alone is 
responsible for the long-lasting elevation in excitability or whether use of methamphetamine and 
other drugs is important. Individuals who use methamphetamine have a history of other drug use 
(e.g. Table 1; McCann et al., 1994, Scholey et al., 2004) and it is not possible to differentiate the 
effects of methamphetamine alone from the combined effects of methamphetamine and other drugs. 
The latter may be important given that ingredients in alcohol and cigarettes inhibit monoamine 
oxidase (Tabakoff et al., 1985, Lewis et al., 2012) which may further impair monoamine 
neurotransmission in methamphetamine users by decreasing the rate of dopamine degradation in the 
cytosol. Third, interpretation of TMS data for female ecstasy users is limited due to difficultly in 
recruiting female participants with a history of ecstasy use but minimal amphetamine use (n=2 
females in the ecstasy group). 
 
4.1 Conclusions 
The results of the current study suggest that use of illicit amphetamines (in particular 
methamphetamine), but not ecstasy, is associated with abnormal manipulation of novel objects in 
abstinent young adults. Elevated excitability in the hand representation of the motor cortex and the 
corticomotoneuronal pathway to hand muscles is also present in abstinent male amphetamine users 
but not in abstinent female amphetamine users. The abnormalities are long-lasting and provide 
further insight into the consequences of methamphetamine use on the human brain and movement. 
Further research is required to determine if these abnormalities are clinically significant and if these 
abnormalities could be used as an objective index of methamphetamine-induced damage and 
recovery in addiction and rehabilitation settings. The results may also guide exploration of the 
potential therapeutic use of rTMS for treatment of methamphetamine addiction (Makani et al., 
2017). 
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Legends  
Figure 1. Study 1 experimental apparatus and data from three participants in the grip and lift task. 
A) Experimental apparatus for the grip and lift task. The index finger and thumb contacted the 
experimental apparatus on two polished brass disks positioned 35 mm apart. B-D) Raw traces of 
grip force (top panel), load force (middle panel), and acceleration (bottom panel) for one participant 
in the non-drug-using group (B), ecstasy group (C), and amphetamine group (D) during the first 
trial of the grip and lift task. Vertical dotted lines show the start and end of the lift phase (0 s (lift 
onset) −1.5 s) and hold phase (1.5−2.5 s). E-G) Temporal characteristics of the grip force and load 
force derived from the raw data presented in B-D. The derivative of grip force (dGF/dt, inset) was 
correlated with the derivative of load force (dLF/dt) and the resultant cross-correlogram is shown 
for each participant. Vertical dotted lines in E-G represents the time shift required to achieve the 
maximal cross-correlation coefficient. 
 
Figure 2. Group data (mean±SD) showing parameters measured during the hand function tasks in 
the non-drug (circles), ecstasy (triangles), and amphetamine (squares) groups. A) Average grip 
force during the lift phase of the grip and lift task. B) Average grip (black symbols) and load (white 
symbols) force during the hold phase of the grip and lift task. C) Average maximum rate of change 
in grip force (i.e. derivative of grip force) during the lift phase of the grip and lift task. D) Average 
maximum cross-correlation coefficient during the lift phase of the grip and lift task. The cross-
correlation coefficient was derived from cross-correlation of the rate of change (derivative) of grip 
force and load force. The maximum cross-correlation coefficient is an index of the temporal 
relationship between changes in grip force and load force. E) Average time to complete the grooved 
pegboard test. * Significant difference across trials (p<0.019). § Significant difference between 
amphetamine and non-drug group (p<0.025). † Significant difference between the amphetamine and 
ecstasy group (p=0.045). 
 
Figure 3. Single participant and group data (mean±SD) showing the amplitude of the resting motor 
evoked potential (MEP) following single-pulse TMS delivered at an intensity of 130% of resting 
motor threshold. A) Averaged EMG traces from one representative participant in each group 
showing the amplitude of the resting motor evoked potential. Arrows indicate the timing of the 
TMS pulse. Vertical dashed lines show the start and end of the motor evoked potential in the non-
drug-using participant. B) Group data showing the average resting MEP amplitude. White bars, all 
participants in the group. Dark grey bars, male participants in the group. Light grey bars, female 
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participants in the group. § Significant difference between amphetamine and non-drug group 
(p<0.005). † Significant difference between the amphetamine and ecstasy group (p=0.021). 
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Tables 
 Study 1: Hand function Study 2: Excitability 
Parameter Non-drug Ecstasy Amphet Non-drug Ecstasy Amphet 
Age (yrs) 24.4±7.7 22.4±2.5 31.4±6.9 *§ 22.8±3.9 21.7±2.5 26.3±4.1 *§ 
Sex 28 M, 18 F 16 M, 8 F 12 M, 7 F 9 M, 9 F 9 M, 2 F 6 M, 6 F 
Handedness 43 R, 3 L 23 R, 1 L 18 R, 1 L 18 R, 0 L 11 R, 0 L 11 R, 1 L 
Educ (yrs) 15.5±2.3 15.7±2.2 14.6±2.9 15.9±2.5 16.2±2.7 14.9±2.3 
BDI-II score 5.8±7.4 9.4±6.6 * 7.0±6.2 3.1±2.8 10.4±6.4 * 10.5±7.9 * 
Diagnosis 0 3 3 0 2 3 
Alcohol 
(drinks) 
(80%) 
1,042±3,525 
(100%) 
3,222±4,218 * 
(100%) 
8,430±8,009 * 
(67%)     
511±804 
(100%) 
2,584±2,727 * 
(100%) 
5,285±4,608*§ 
Tobacco 
(cigarettes) 
(24%)    
22±53 
(88%)  
5,124±12,706 
(89%)   
45,662±52,085*§ 
(22%)     
5±3 
(100%) 
4,721±7,418 * 
(100%) 
14,027±16,229*§ 
Ecstasy (0%) 
(100%) 
38±51 
(89%)     
97±127 
(0%) 
(100%) 
35±50 
(100%)     
82±64 
Methamphet (0%) 
(38%)       
1±1 
(89%)         
636±1,252 
(0%) 
(45%)       
1±0 
(92%)         
449±623 
Cocaine (0%) (50%) 2±2 (58%) 6±8 (0%) (27%) 2±2 (58%) 8±10 
Pharmaceut (0%) (17%) 2±0 (32%) 18±36 (0%) (18%) 2±0 (25%) 34±51 
Cannabis 
(7%)       
1±1 
(100%)   
457±1,036 
(100%) 
3,031±2,971 § 
(0%) 
(91%)     
753±1,362 
(100%) 
1,270±1,678 
Hallucinogen (0%) (79%) 18±32 (84%) 83±164 (0%) (91%) 18±43 (92%) 60±100 
Inhalant (0%) (33%) 49±69 (58%) 65±98 (0%) (45%) 69±83 (75%) 19±33 
Sedative (0%) (17%) 2±1 (47%) 12±22 (0%) (0%) (67%) 3±2 
Opioid (0%) (13%) 3±1 (42%) 4±4 (0%) (9%) 4 (33%) 2±1 
 
Table 1. Participant characteristics for the non-drug, ecstasy, and amphetamine groups in Study 1 
and 2. Data presented are mean±SD, except for lifetime drug use parameters which are presented as 
the percentage of participants who have used a class of drug and the mean±SD for the lifetime 
occasions of use in brackets. ‘Diagnosis’ refers to the number of participants who had received a 
formal diagnosis of depression and/or anxiety after commencement of illicit drug use. The term 
‘ecstasy’ includes MDMA (3,4-methylenedioxymethamphetamine) and MDA (3,4-
methylenedioxyamphetamine). The term ‘pharmaceutical stimulant’ (pharmaceut) includes illicit 
use of methylphenidate and dexamphetamine. The term ‘hallucinogens’ includes LSD (lysergic acid 
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diethylamide), LSA (d-lysergic acid amide), ‘magic mushrooms’, mescaline, DOI (2,5-dimethoxy-
4-iodoamphetamine), DMT (dimethyltryptamine), JWHO18 (synthetic cannabis), 2CI/2CB (2,5-
dimethoxy-4-iodophenethylamine or 2-(4-bromo-2,5-dimethoxyphenyl) 
ethanamine), ketamine, NBOMe (N-methoxybenzyl), salvia divinorum, and datura. The term 
‘inhalants’ includes amyl nitrate, nitrous oxide, and ethyl chloride. The term ‘sedatives’ includes 
GHB/fantasy and illicit use of benzodiazepines, pregabalin, antihistamines, and antidepressants. 
The term ‘opioids’ describes opium and heroin and illicit use of methadone, oxycodone, 
buprenorphine, morphine, and/or codeine. * Significantly different from the non-drug group 
(P<0.05). § Significant difference between ecstasy and amphetamine groups (P<0.001).  
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